Manju Shri

Manju Shri

Active Director Director DIN 07812038
DIN 07812038 First appointment Nov 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2017
Shareholding value •••• Premium profile

About Manju Shri

Data last updated:

Manju Shri is a Director at Augment Pharmaceutical Private Limited (since 2017). The company operates in Pharma. Augment Pharmaceutical Private Limited reported revenue of ₹13.4 Lakh (FY 2024).

DIN 07812038
Primary Designation Director
Industry Pharma
First Appointment 06 Nov 2017
Oldest Company Age 9 yrs
Largest company Augment Pharmaceutical Private Limited · ₹13.4 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Nov 20172017₹13.4 Lakh (FY 2024)Active

Board colleagues of Manju Shri

NameDINCompanyDesignation
Sunil Kumar Ajar07812055Augment Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Augment Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Manju Shri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manju Shri

Manju Shri currently holds 1 directorship: Augment Pharmaceutical Private Limited (Director, since 06 Nov 2017, revenue ₹13.4 Lakh (FY 2024)).

Manju Shri was first appointed on 06 Nov 2017 as Director at Augment Pharmaceutical Private Limited.

The current boards of Manju Shri's companies include Sunil Kumar Ajar (Augment Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available